Lonza has agreed to take over the contract development and manufacturing business inside Merck KGaA's Life Science sector, covering five US facilities and about 1,100 employees, as PharmaSource's report on the five locations describes it. Closing is not expected until mid-2027, according to Pharmexec's coverage of the five sites. For a program that needs US capacity in the next eighteen months, the site on your shortlist still belongs to Merck. The question is what you are contracting with, and for how long.
What the transfer adds to Lonza's US footprint
The sources agree on the core facts. Lonza gets bioconjugate, payload-linker, and viral vector capacity, which is a narrower and more specialized set than a general biologics expansion. BioXconomy's piece on the portfolio reshuffle frames the deal as a way to add US manufacturing aligned with demand for complex medicines. Bioprocess International reads the same transaction differently: as another step in Lonza's portfolio reshaping, paired with Merck KGaA narrowing toward its core life science business.
Those framings are not contradictory, but they point buyers at different questions. The capacity story asks whether the sites can take on your programs. The portfolio story asks whether the seller and buyer will keep investing in those sites after the deal. Neither source settles that.
The price is also not in the public record in any useful detail. PharmaSource reports the deal value as in the mid-triple-digit million-euro range, while Endpoints News notes that the finer financial details were not laid out. A buyer should not read valuation into the acquisition and should not assume the sellers have signaled how much they will invest in the sites during the interim period.
Consolidation: one deal is not yet a pattern
The internal framing for this piece talks about major players acquiring US manufacturing assets as a trend. The evidence here supports one transaction. It is a large, visible one, with five sites, a defined product focus, and a long close. It is not, on its own, proof that a wave of similar deals is underway. If your procurement model assumes that US sites will keep changing hands at this pace, you need other transactions in the record to justify that assumption.
What one deal does show is a more practical pattern: capacity in specialized modalities can move between owners on a timeline of more than a year, and the buyer's contract sits on top of that timeline. A sponsor who signed with a Merck site in 2025 may find itself negotiating with Lonza in 2027. The vendor relationship you thought was stable is in fact a relationship with a site that is in transition.
Questions worth putting in the next RFP
When a site is being sold, the RFP and the contract need to cover the ownership change directly, not as a footnote. The following questions are worth asking any CDMO that has a US site in a pending transaction, whether it is the seller, the buyer, or a bystander with a capacity reservation:
- Which legal entity will hold the quality agreement and the manufacturing license on the day after closing, and what changes between signing and closing?
- Will any change-control or regulatory filing be needed for a change of ownership, and who carries the cost and timeline risk if inspection or filing dates slip past mid-2027?
- Will the staff who run your program (process development, QA release, and technology transfer contacts) remain in place through the transition? The Lonza deal covers about 1,100 employees, and buyers should ask how many of those people are on their programs.
- If the modality is bioconjugate or viral vector, what supply continuity plan exists for raw materials and single-use components that the seller currently sources through Merck group contracts?
- What happens to your reserved cap
Sources
- Daily news digest — Lonza Acquires Merck KGaA's CDMO Business to Enhance US Manufacturing Capacity
- Pharmaceutical Executive RSS — Lonza to Acquire Five U.S. CDMO Sites From Merck KGaA
- BioProcess International RSS — Portfolio reshuffle: Lonza buys Merck KGaA's CDMO arm
- Endpoints News RSS — Updated: Merck KGaA is selling its CDMO business in the US to Lonza
- PharmaSource RSS — Lonza to Acquire Merck CDMO Operations Across Five US Locations